Navigation Links
Study shows drug effective in treating, preventing breast cancer
Date:11/1/2007

CORVALLIS, Ore. A new study of an estrogen-derived drug shows promise as a treatment for breast cancer and breast cancer metastases to bone.

The study, which was done in mice, appears on the cover of the November issue of Cancer Research.

Urszula Iwaniec, an assistant professor in the Department of Nutrition and Exercise Sciences at OSU, is the one of the authors of the study, along with OSU professor Russell Turner and researchers from the Mayo Clinic. Iwaniec and Turner are both researchers at OSUs Skeletal Biology Laboratory.

In breast cancer, the cancer commonly lodges in the bone, destroying it in a debilitating painful process called osteolysis. Osteolysis can lead to bone fractures and causes patients to feel tired, or even to lose consciousness.

Iwaniec and Turner studied the effect of 2-methoxyestradiol (meth-oxy-es-tra-di-ol), or 2ME2, on the bone. 2ME2 is derived from estrogen and works by suppressing tumor growth and blocking the formation of new blood vessels that feed tumors.

We were expecting the drug to have an effect, but we were not expecting to have as big of an effect as it did, Iwaniec said.

In studies of other cancers, 2ME2 has been shown to induce cancer cells to self-destruct. Otherwise, tumor cells evade this process allowing them to continually divide and spread throughout the body.

Clinical trials of 2ME2 for breast cancer patients are in progress. These trials are based on an oral version of 2ME2 to treat primary tumors, but this method has limitations as the oral version of 2ME2 is poorly suited to getting into the blood system and reaching tumors. Researchers resolved this problem by delivering 2ME2 by injection and found it was much more effective.

Researchers described 2ME2 as an attractive candidate for controlling tumor growth, metastasis to bone and bone disorders, such as osteolysis caused by the spread of breast cancer.

This is potentially of very substantial importance because this agent has few of the unpleasant side effects of most chemotherapy drugs and targets both bone resorption and the cancerous tumor cells, Turner said. It really is the first agent that has been clearly demonstrated to do that.

Turner said current drugs that are used to prevent bone fractures and bone pain in cancer patients are not effective in targeting the tumor cells. Turner has spent the past decade studying 2ME2 as a treatment for osteoporosis and a rare bone cancer called osteosarcoma, and is excited about its prospects as a cancer treatment.

Often, treatments that are good for cancer are bad for the bones, he said. 2ME2 appears to be capable of treating both. If you had a treatment that both reduced the risk of bone cancer and osteoporosis, it would be extremely significant.

In summary, the researchers found that 2ME2 could:

  • Effectively target breast cancer cells;
  • Prevent the spread of breast cancer cells to bone;
  • Protect bone from osteolysis, which is a type of bone metastasis in which the bone is eaten away by cancer cells.

The next step for the Mayo Clinic and OSU researchers is to replicate and test the finding in clinical trials.


'/>"/>

Contact: Urszula Iwaniec
urszula.iwanie@oregonstate.edu
541-737-9925
Oregon State University
Source:Eurekalert

Related medicine news :

1. Rural Canadians travel far for specialists: study
2. A new study surpasses Gene Therapy Hurdle
3. Tomato Sauce reduces Cancer Risk- Study
4. A question on study of Adult Stem Cell
5. Study on obesity and heart failure
6. National Lung Study in the process
7. Marijuana gateway theory strengthened by study of twins
8. Old theory of adaptation confirmed by new study
9. Study casts doubt on keyboard ills
10. Gene study links endometriosis, infertility
11. Study reveals how stress can make you sick
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... ... Einstein Medical is proud to announce that it has created ... at the 2016 ASCRS/ASOA Symposium and Congress, which takes place in New Orleans, LA ... Surgery and the American Society of Ophthalmic Administrations will be held at the Ernest ...
(Date:5/5/2016)... ... May 05, 2016 , ... Spring ... results with IVF and with egg freezing, today announced the grand opening of ... highest quality fertility care, Spring Fertility offers both fertility preservation (egg, sperm, embryo, ...
(Date:5/5/2016)... ... 05, 2016 , ... United Benefit Advisors (UBA), the nation’s ... latest addition to its family of Partner Firms. Headquartered in Mount Pleasant, South ... resources, and health care consumerism specialists. , “Partnering with UBA will enable our ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... ... commencement of a master charity program created to assist the people of their ... working closely with nonprofit organizations and community leaders. Their hope is to bring ...
(Date:5/5/2016)... ... May 05, 2016 , ... Tim Dieter ... serving families of greater Dubuque, IA. The current campaign fundraises for Veteran’s Freedom ... veterans. Donations to Veteran’s Freedom Center may now be made here: http://www.veteransfreedomcenter.com/donate/ ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... , May 5, 2016 ... of the  "Europe Thalassaemia Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Thalassaemia Market and Competitive Landscape Highlights - ... products, Thalassaemia epidemiology, Thalassaemia market valuations and ...
(Date:5/4/2016)... 2016  Compass Diversified Holdings (NYSE: CODI ... of leading middle market businesses, announced today its consolidated ... 2016. First Quarter 2016 Highlights , ... or "Cash Flow") of $13.6 million for the first ... $15.0 million for the first quarter of 2016; ...
(Date:5/4/2016)... 4, 2016  It,s time for an upgrade. There are many medical recorders on ... inch LCD, the illustrious DVMAXX HD  offers unparalleled connectivity and functionality.  Ampronix  is ... world class manufacturer of innovative technology.  Photo - http://photos.prnewswire.com/prnh/20160503/363416 ... ... ...
Breaking Medicine Technology: